Plain language summary {#S0001}
======================

**Why was the study done?**

Some patients with COPD have high blood eosinophil counts, which may be associated with severe disease. Such patients experience episodes of frequent symptom worsening, known as exacerbations, despite receiving the recommended treatment (inhaled triple therapy). There are currently limited real-world data in these patients.

**What did the researchers do and find out?**

This study used de-identified electronic medical records to describe patients with COPD and ≥1 recorded blood eosinophil count. We described the proportion of patients with COPD who had: (1) prescriptions for inhaled triple therapy, (2) blood eosinophil count ≥150 cells/µL, and (3) ≥2 moderate/≥1 severe exacerbation in the previous year. Patients who met these criteria were referred to as having the study phenotype. These patients had an increased rate of exacerbations, GP visits and non-COPD-related unscheduled hospitalizations, and death compared with those who did not have the study phenotype.

**What do these results mean?**

Patients with COPD who continue to experience exacerbations despite receiving the recommended treatment and have high blood eosinophil levels have a high clinical burden of illness. These patients could benefit from more effective management programs.

Introduction {#S0002}
============

High clinical burden of illness in COPD is well recognized. Acute exacerbations of COPD (AECOPDs) are key drivers of morbidity and mortality among patients with COPD.[@CIT0001]--[@CIT0003] Patients experiencing frequent exacerbations have significantly worse health-related quality of life compared with those experiencing infrequent exacerbations,[@CIT0004] and each hospitalized AECOPD can lead to a substantial decline in lung function.[@CIT0005] In addition, patients experiencing hospitalized AECOPDs have a higher risk of mortality than those who do not experience this event.[@CIT0006],[@CIT0007]

Pharmacological and non-pharmacological therapies for COPD aim to alleviate symptoms and reduce the risk and severity of exacerbations; indeed, studies based on healthcare data have shown that continued COPD exacerbations are the most significant drivers of treatment escalation in the clinic.[@CIT0008]--[@CIT0011]In recognition of the significant proportion of patients with COPD who continue to experience frequent exacerbations, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) report has extended its recommendations to include treatment escalation strategies.[@CIT0001] Since 2017, GOLD has recommended escalation to triple therapy comprising inhaled corticosteroid (ICS)/long-acting β~2~-agonist (LABA)/long-acting muscarinic antagonist (LAMA) for patients with COPD who continue to experience persistent symptoms or further exacerbations despite treatment with ICS/LABA or LABA/LAMA dual therapy. However, it has been reported that approximately 30--50% of the patients receiving ICS/LABA/LAMA triple therapy continue to experience frequent or hospitalized exacerbations.[@CIT0012]--[@CIT0017]

As such, there is a substantial unmet need for more effective therapeutic options for patients who continue to exacerbate despite receiving ICS/LABA/LAMA triple therapy. Recent studies have demonstrated that, like asthma, COPD is a heterogeneous condition comprising several different phenotypes; therefore, patients may benefit from more tailored therapeutic approaches that are based on particular phenotypic or endotypic traits.[@CIT0018] For example, a subset of patients with COPD demonstrate increased eosinophilic airway inflammation during exacerbations.[@CIT0019] Furthermore, peripheral blood eosinophil counts of ≥150 cells/µL have been shown to be associated with an increased risk of AECOPDs.[@CIT0019]--[@CIT0021] Importantly, patients with increased blood eosinophil counts have a greater probability of benefit from treatment with ICS[@CIT0013],[@CIT0022]--[@CIT0024] and treatments that specifically target eosinophilic inflammation.[@CIT0025]

The aims of this study were to describe clinical burden of illness in patients with COPD at high risk of exacerbations while receiving ICS/LABA/LAMA multiple-inhaler triple therapy (MITT) and blood eosinophils ≥150 cells/µL and compare these outcomes in patients with COPD without this phenotype.

Materials and methods {#S0003}
=====================

Study design and data source {#S0003-S2001}
----------------------------

This was a retrospective cohort study conducted using electronic medical records from the UK Clinical Practice Research Datalink (CPRD). The CPRD database contains anonymized, longitudinal primary care medical records of patients registered with contributing general practitioners.[@CIT0026] Information contained within the database includes patient registration information and demographics, prescriptions issued in primary care, clinical events, immunizations, referrals to specialists and secondary care settings, lifestyle information, and date of death.[@CIT0026] Primary care data from CPRD were linked to secondary healthcare data from Hospital Episode Statistics (HES) in England, producing a linked dataset (hereafter referred to as CPRD-HES) with comprehensive, fully de-identified, patient-level primary and secondary care data. The study was approved by the CPRD Independent Scientific Advisory Committee on January 26, 2017 (protocol identifier: 16_295).

An overview of the study design is provided in [Figure S1](#SF0001). Eligible patients were aged ≥35 years with a validated COPD medical diagnosis code[@CIT0027] recorded between January 1, 2004 and December 31, 2014, and a forced expiratory volume in 1 s/forced vital capacity \<0.7 at any time. Additionally, patients were required to have a qualifying peripheral blood eosinophil count recorded between January 1, 2010 and December 31, 2014, defined as an eosinophil count record that occurred on or after the date of COPD diagnosis, contained at least one non-missing result, and had ≥12 months of patient clinical history preceding the record. The date of the first qualifying eosinophil count was defined as the patient's index date. Patients were followed from their index date to the first of: end of study (December 31, 2015); patient death; patient left the general practitioner (GP) practice; or, the GP practice stopped providing data to CPRD.Figure 1Proportion of patients meeting each defining criterion of the study phenotype, Numbers of patients meeting each criterion were as follows: EOS: n=19,303 (41.2%); MITT: n=2504 (5.3%); AECOPD: n=2094 (4.5%); MITT/EOS: n=4,845 (10.3%); AECOPD/EOS: n=3923 (8.4%); AECOPD/MITT: n=1408 (3.0%); Study phenotype: n=2512 (5.4%); no criteria: n=10,225 (21.8%). AECOPD, ≥2 moderate or ≥1 severe acute exacerbation of COPD in the 12 months prior to the index date; EOS, blood eosinophil count ≥150 cells/µL on the index date; MITT, multiple-inhaler triple therapy use on the index date. Study phenotype is defined as patients with ≥2 moderate or ≥1 severe acute exacerbation of COPD in the 12 months prior to the index date, who were receiving multiple-inhaler triple therapy at the index date, and who had a peripheral blood eosinophil count ≥150 cells/µL recorded on the index date.**Abbreviation:** AECOPD, acute exacerbation of COPD.

Patients were excluded from the study if they had \<365 days up-to-standard data available in CPRD prior to the index date (earliest qualifying eosinophil count) or a diagnosis of a condition that either severely modifies the natural course of COPD or where COPD could be a secondary diagnosis, such as fibrotic processes (idiopathic, cystic), lung resection, and/or transplantation or lung congenital malformations.

Definition of the study phenotype {#S0003-S2002}
---------------------------------

From the pool of eligible patients identified from the CPRD-HES database, a subgroup of patients who had the study phenotype of interest were selected. The study phenotype was defined as having ≥2 moderate or ≥1 severe AECOPD in the 12 months prior to the index date, plus current prescriptions for MITT on the index date, plus a peripheral blood eosinophil count of ≥150 cells/µL recorded on the index date. The cut point of ≥150 cells/µL is consistent with that used in other published studies.[@CIT0028]--[@CIT0030] A moderate AECOPD was defined based on a validated algorithm using a combination of recorded respiratory symptoms, exacerbation or lower respiratory tract infection diagnoses, and prescriptions for oral corticosteroids and/or antibiotics recorded in CPRD data only.[@CIT0031] A severe AECOPD was defined as a hospitalized exacerbation, identified using HES inpatient data.[@CIT0032] MITT use was defined as overlapping prescriptions of a LAMA combined with an ICS and a LABA, delivered via two or three devices. Patients who did not meet all the above criteria were considered not to have the study phenotype.

Outcomes {#S0003-S2003}
--------

Clinical burden of illness was assessed using the following outcomes: rate of moderate/severe AECOPD, rate of severe AECOPD, and rate of all-cause mortality. Health-Care Resource Utilization (HCRU) outcomes included primary (GP) clinical consultations and non-AECOPD-related uncheduled hospitalizations.

Sample size and statistical analysis {#S0003-S2004}
------------------------------------

Based on an expected sample size of 43,200 with 2.8% (approximately 1200) patients with the study phenotype and an average follow-up of 1 year, the analysis had \>90% power to detect rate/hazard ratios of 1.2--2.0 for all outcomes except for severe AECOPD (\>90% to detect rate ratios of 1.4 or greater) and all-cause mortality (\>90% power to detect hazard ratios of 1.4 or \>80% power to detect hazard ratios of 1.8 or greater, depending on baseline mortality).

With the exception of all-cause mortality, rate ratios for all outcomes were estimated using negative binomial regression. For all-cause mortality, hazard ratios were estimated using Cox proportional hazards regression. For all HCRU outcomes, annualized rates were calculated using the subset of patients with ≥12 months of follow-up after their index date. The following variables were included as pre-specified covariates in all models: age; sex; ethnicity; region; social deprivation (as measured by the Index of Multiple Deprivation); month of index date; body mass index (BMI) group; smoking status; number of primary care consultations in the 12 months prior to the index date; prior comorbidity including depression, anxiety, gastroesophageal reflux disease, lung cancer, acute myocardial infarction, congestive heart failure, and stroke. These variables are potential confounders and effect modifiers in the comparison of those patients with and without the study phenotype. Furthermore, patients without the study phenotype would be expected to have a milder course of COPD than those with the study phenotype based on the qualifying criteria. For this reason, variables directly related to COPD clinical severity were not included as covariates in any of the models, to allow for quantification of real differences between those patients with the study phenotype and those without.

Two sensitivity analyses were conducted to assess the strength of the study phenotype definition. In each sensitivity analysis, one defining criterion of the study phenotype was adjusted, while the other two were kept constant. In the first sensitivity analysis, the peripheral blood eosinophil count required on the index date was increased from ≥150 cells/µL to ≥300 cells/µL (study phenotype~S1~). This sensitivity analysis was conducted to address the fact that in published literature various thresholds for blood eosinophils have been explored as markers of COPD disease activity and therapeutic response. In a second sensitivity analysis, patients were required to have continuous MITT use for ≥12 months prior to the index date, instead of current MITT use on the index date (study phenotype~S2~), to exclude any cases where MITT was initiated shortly prior to the index date.

Results {#S0004}
=======

Patient population {#S0004-S2001}
------------------

Of the 7.05 million patients included within the CPRD-HES dataset at the time of analysis, 46,814 were eligible for inclusion in this study, and 2512 (5.4%) met the definition of the study phenotype ([Figure S2](#SF0002)). Overall, 10,225 patients (21.8%) did not meet any of the study phenotype criteria (ie, did not have ≥2 moderate or ≥1 severe AECOPD in the 12 months prior to the index date, a current prescription for MITT on the index date, or a peripheral blood eosinophil count of ≥150 cells/µL). A total of 11,269 patients (24.1%) were currently treated with MITT on their index date, 9937 patients (21.2%) experienced ≥2 moderate or ≥1 severe exacerbations in the 12 months prior to their index date, and 30,583 patients (65.3%) had blood eosinophils ≥150 cells/µL on their index date. Notably, of the 11,269 patients with current MITT use on the index date, 3920 (34.8%) also experienced frequent exacerbations in the prior year. The proportions of patients who fulfilled each combination of the three study phenotype criteria are shown in [Figure 1](#F0001){ref-type="fig"}.Figure 2Unadjusted rates of clinical burden of illness outcomes during follow-up for patients with and without the study phenotype. Study phenotype is defined as patients with ≥2 moderate or ≥1 severe AECOPD in the 12 months prior to the index date, who were receiving multiple-inhaler triple therapy at the index date, and who had a peripheral blood eosinophil count ≥150 cells/µL recorded on the index date. Patients who did not meet all three of the criteria were classified as being in the non-study phenotype.**Abbreviation:** AECOPD, acute exacerbation of COPD.

Age and gender distributions were similar across the patients with and without the study phenotype ([Table 1](#T0001){ref-type="table"}). Overall, patients with the study phenotype experienced more severe COPD based on a distribution of GOLD 2017 groups and their components but had similar levels of comorbidities and smoking status as patients without the study phenotype ([Table 1](#T0001){ref-type="table"}).Table 1Baseline demographic and clinical characteristics of patients with and without the study phenotypeStudy phenotype\
present\
(N=2512)Study phenotype\
absent\
(N=44,302)**Sex, male, n (%)**1303 (51.9)23,637 (53.4)**Age at index date, years, n (%)** Mean (SD)70.1 (10.3)71.0 (10.7)**Smoking status nearest prior to index date, n (%)** Ex-smoker1579 (62.9)25,374 (57.3) Non-smoker86 (3.4)3057 (6.9) Current smoker847 (33.7)15,871 (35.8)**Comorbidities any time prior to index date, n (%)** Current asthma^a^547 (21.8)8547 (19.3) Anxiety473 (18.8)7485 (16.9) Depression424 (16.9)6232 (14.1) GERD476 (18.9)7328 (16.5) Heart failure241 (9.6)3227 (7.3) Myocardial infarction245 (9.8)3843 (8.7) Stroke140 (5.6)2308 (5.2) Herpes zoster319 (12.7)5091 (11.5) Lung cancer49 (2.0)552 (1.2)**GOLD 2017[@CIT0038] within 24 months prior to index date (using MRC dyspnea score), n (%)**N=2246N=36,891 GOLD A017,983 (48.7) GOLD B012,767 (34.6) GOLD C691 (30.8)2566 (7.0) GOLD D1555 (69.2)3575 (9.7) Unknown/missing2667411**FEV~1~% predicted grade, n (%)**N=2,210N=37,663 Grade 1107 (4.8)4128 (11.0) Grade 2809 (36.6)20,559 (54.6) Grade 3947 (42.9)10,753 (28.6) Grade 4347 (15.7)2223 (5.9) Unknown/missing3026639**MRC in the 24-month pre-index period, n (%)**N=2,246N=36,891 Grade 1140 (6.2)6412 (17.4) Grade 2551 (24.5)14,137 (38.3) Grade 3738 (32.9)9541 (25.9) Grade 4652 (29.0)5550 (15.0) Grade 5165 (7.3)1251 (3.4) Unknown/missing2667411**Eosinophil value measured on index date, n (%)** Geometric mean (95% CI)294.5 (292.6--296.4)193.4 (193.0--193.8) ≥150 cells/µL2512 (100.0)28,071 (63.4) ≥300 cells/µL1271 (50.6)13,558 (30.6) ≥500 cells/µL391 (15.6)3747 (8.5)≥1 moderate/severe AECOPDs in the 12-month pre-index period, n (%)2512 (100.0)17,002 (38.4)≥1 severe AECOPDs in the 12-month pre-index period, n (%)969 (38.6)2725 (6.2)Number of days exposed to MITT in the 12-month pre-index period, mean (SD)252.1 (116.1)75.3 (120.8)Number (%) with theophyllines (slow-release)^b^414 (16.5)2160 (4.9)Number (%) with chronic OCS exposure (≥4 OCS prescriptions with ≤28-day gap in a row)^b^250 (10.0)1390 (3.1)Number (%) with chronic antibiotic exposure (≥4 antibiotic medication prescriptions with ≤28-day gap in a row)^b^401 (16.0)1755 (4.0)[^1][^2]

Clinical burden of illness outcomes {#S0004-S2002}
-----------------------------------

Mean follow-up time was similar for patients with and without the study phenotype criteria (2.3 years vs 2.5 years, respectively). The rates of all clinical burden of illness outcomes were higher in patients with the study phenotype, versus those without. The crude rate of moderate/severe AECOPDs in patients with the study phenotype was 2.29 events per person-year, compared with 0.89 events per person-year in patients without the study phenotype. Similarly, crude rates of severe AECOPDs and all-cause mortality were higher among patients with the study phenotype, compared with those without (0.42 vs 0.15 events per person-year and 0.10 vs 0.07 events per person-year, respectively; [Figure 2](#F0002){ref-type="fig"}).

After adjusting for potential confounders, patients with the study phenotype were found to have an increased rate ratio (95% CI) of 2.32 (2.22, 2.43) for moderate/severe AECOPDs, and 2.34 (2.15, 2.55) for severe AECOPDs, compared with patients without the study phenotype ([Figure 3A](#F0003){ref-type="fig"}). Additionally, patients with the study phenotype had an adjusted hazard ratio (95% CI) for all-cause mortality of 1.26 (1.16, 1.37), compared with patients without the study phenotype ([Figure 3A](#F0003){ref-type="fig"}).Figure 3Adjusted rate ratios of clinical burden of illness outcomes and hazard ratios for all-cause mortality for (**A**) patients with vs without the primary study phenotype, (**B**) patients with vs without study phenotype~S1~, and (**C**) patients with vs without study phenotype~S2~. Primary study phenotype is defined as patients with ≥2 moderate or ≥1 severe AECOPD in the 12 months prior to the index date, who were receiving multiple-inhaler triple therapy at the index date, and who had a peripheral blood eosinophil count ≥150 cells/µL recorded on the index date. For study phenotype~S1~, the peripheral blood eosinophil count required on the index date was increased to ≥300 cells/µL. For study phenotype~S2~, patients were required to have been receiving continuous multiple-inhaler triple therapy for ≥12 months prior to the index date. For each analysis, patients who did not meet all three of the criteria were classified as being in the non-study phenotype. Rate ratios adjusted for age, sex, geographical region in England, body mass index, smoking status, comorbidities, Index of Multiple Deprivation (twentiles, modeled as a continuous variable), primary care consultations in prior year, and season of index date. Rate ratios were calculated for all outcomes except for all-cause mortality where a hazard ratio was calculated.**Abbreviation:** AECOPD, acute exacerbation of COPD.

HCRU outcomes {#S0004-S2003}
-------------

For HCRU analysis, the study population was limited to 36,780 patients who had at least 12 months of follow-up data after their index date. Of these, 660 had the study phenotype and 36,120 did not. Compared with the primary study population, no meaningful differences in the characteristics of this subpopulation were observed. Crude rates of GP visits and unplanned non-AECOPD-related hospitalizations were higher in patients with the study phenotype compared with patients without the study phenotype (10.32 vs 8.35 events per person-year, and 0.42 vs 0.26 events per person-year, respectively; [Figure S3](#SF0003)). In addition, adjusted rates of both HCRU outcomes were significantly higher among patients with the study phenotype versus those without, with a 9% increased rate of GP visits and a 31% increased rate of non-AECOPD-related unscheduled hospitalizations ([Figure S4A](#SF0004)).

Sensitivity analysis {#S0004-S2004}
--------------------

When the blood eosinophil count threshold used to define the study phenotype was increased from ≥150 cells/µL to ≥300 cells/µL (study phenotype~S1~), the number of patients who met the definition of the study phenotype decreased to 1271 (2.7%). Baseline characteristics such as age and gender were similar in both the primary study phenotype and study phenotype~S1~ populations. The adjusted rate ratios and hazard ratios (95% CI) of moderate/severe AECOPDs, severe AECOPDs and all-cause mortality in patients with vs without the study phenotype~S1~ were 2.30 (2.15, 2.45), 2.25 (2.01, 2.53), and 1.21 (1.07, 1.36), respectively ([Figure 3B](#F0003){ref-type="fig"}). This increased disease burden in those patients with the study phenotype is consistent with the primary analysis.

When the MITT criterion used to define the study phenotype was changed from current MITT use on the index date to continuous MITT use for ≥12 months preceding the index date (study phenotype~S2~), the size of the population that fulfilled all three study phenotype criteria decreased to 851 patients (1.8%). Again, baseline characteristics were broadly similar between the primary study phenotype population and the study phenotype~S2~ population, with the exception that the latter had a slightly higher proportion of patients in GOLD group D within 24 months prior to the index date (61.9% vs 67.8%). Overall, patients meeting the definition of study phenotype~S2~ experienced marginally higher rates of AECOPDs and all-cause mortality (within 10% relative difference) compared with patients meeting the primary study phenotype definition ([Figure 3C](#F0003){ref-type="fig"}).

The relative rates of all HCRU outcomes were similar when using the primary study phenotype, study phenotype~S1ʹ~ and study phenotype~S2~ definitions ([Figure S4](#SF0004)).

Discussion {#S0005}
==========

This study investigated the clinical burden of illness among patients with severe eosinophilic COPD, defined here as patients who had ≥2 moderate or ≥1 severe AECOPD in the 12 months prior to the index date, and were receiving MITT and had a peripheral blood eosinophil count ≥150 cells/µL on the index date. This is one of the first studies to characterize this patient population and report the clinical burden of illness among patients with this COPD phenotype, based on information from a real-world database.

From a large cohort of patients (N=46,814), 5.4% fulfilled all three criteria used to define the study phenotype. The rates of all outcomes were substantially higher in the study phenotype population than in patients without the study phenotype; however, patient demographics, lifestyle characteristics, and comorbidities were similar between the two patient populations. Patients with the study phenotype also had a more than two-fold increase in the rate of moderate/severe AECOPDs and a higher hazard ratio for all-cause mortality, compared with patients who did not meet all three study phenotype criteria. Sensitivity analyses in which either the eosinophil threshold required on the index date was increased to ≥300 cells/µL or the MITT criterion was altered to require ≥12 months continuous MITT use prior to the index date, produced similar results to the primary analysis. A higher rate of study outcomes in the population with the study phenotype was expected and driven by the definition of these traits, namely history of exacerbations. A recent study also reported that patients with COPD who had an eosinophil count \>150 cells/µL had higher all-cause and COPD-related healthcare costs than those with an eosinophil count \<150 cells/µL.[@CIT0033] Taken together, these results highlight the high clinical burden of illness among patients with this phenotype and suggest that these individuals have a more severe disease course than other patients with COPD who do not meet the study phenotype criteria. There is need for a consistently identifiable and treatable phenotypic trait that will allow physicians to identify patients at increased risk of frequent COPD exacerbations and poor outcomes and provide appropriate therapeutic interventions.

In the present study, no substantial differences were observed in demographic and lifestyle characteristics between patients with and without the study phenotype. This is consistent with a prior case--control study, in which no significant differences were observed in demographic characteristics between patients with and without frequent COPD exacerbations.[@CIT0034] In contrast, other studies characterizing the COPD frequent exacerbator phenotype have reported that female gender, lower BMI, and severe airflow limitation are associated with more frequent COPD exacerbations.[@CIT0035]--[@CIT0037] Notably, several studies have previously reported that a history of exacerbations is a significant predictor of future exacerbations.[@CIT0035],[@CIT0037]--[@CIT0039] Moreover, elevated eosinophil counts have also been associated with an increased risk of COPD exacerbations in a primary care database analysis,[@CIT0035] and in two post hoc analyses of clinical trials in COPD.[@CIT0023],[@CIT0024] Based on the criteria used in our study, we would expect those patients with the study phenotype to have an increased clinical burden of illness compared with those without, and our results show that this is indeed the case. Based on this and other studies, it seems likely that a history of prior exacerbations plus elevated peripheral blood eosinophil counts could serve as a strong indicator of increased risk for future exacerbations.

The present study had several strengths that increase the clinical relevance of the results. First, the CPRD reflects a representative sample of patients with recognized disease and complete medical care records provided by the UK National Health Service.[@CIT0026] As such, the results of this study have high generalizability within the UK. Second, validated algorithms with high sensitivity and positive predictive values were used to identify patients with COPD and AECOPDs.[@CIT0027],[@CIT0031] Lastly, we conducted sensitivity analyses employing either a more stringent blood eosinophil count threshold or a stricter definition of MITT use. Both sensitivity analyses produced similar results to the primary analysis, indicating that patients with blood eosinophil counts ≥150 cells/µL have similar burden of disease to those with counts ≥300 cells/µL and that patients were generally receiving long-term MITT. Overall, the consistency in the results for the primary analysis population and sensitivity analysis populations demonstrates durability of the phenotype described.

Despite these strengths, there were several limitations inherent to the study design. First, as all patients were required to have at least one blood eosinophil count recorded, many patients within the CPRD-HES database were not eligible for inclusion in this study. However, a recent report demonstrated that the presence of an eosinophil count record in the CPRD database is not associated with any significant trait among patients with COPD.^29^ Second, a single blood eosinophil record was used to determine level of eosinophils. This was a pragmatic decision, given blood eosinophil counts are infrequently recorded with long gaps between records, and supported by good stability in this primary care population as reported previously.[@CIT0030] Moreover, blood eosinophil count records may not have been representative of steady-state counts, as they may have been recorded at the time of acute infection or AECOPD, or during use of antibiotics, ICS, or SCS. As such, patients may have been misclassified as having elevated blood eosinophil counts, or vice versa, although the impact of this limitation should have been minimized by the large cohort size and the fact that primary care data were analyzed (which are mostly recorded during routine care). Third, as ascertainment of patients with COPD, AECOPDs, and MITT use was based on pre-specified coding lists and algorithms, there was potential for misclassification of these events. This issue was mitigated by using previously validated code lists and strategies reviewed by a clinician. Finally, although CPRD contains near-complete records of primary care prescribing, information on dispensing, adherence, and secondary care prescribing is lacking, which may have resulted in misclassification of MITT use.

Conclusion {#S0006}
==========

This study has described a severe eosinophilic phenotype that is present in a small proportion of patients with COPD and have a high risk of adverse disease outcomes. Our findings demonstrate that these patients represent a substantial clinical burden and continue to frequently exacerbate or experience hospital admissions despite receiving ICS/LABA/LAMA triple therapy. As such, these patients may benefit from treatment with additional interventions that specifically target their phenotypic traits.
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Figure S1Overview of study design.**Abbreviation:** GP, general practitioner. Figure S2Patient flow diagram. Study phenotype is defined as patients with ≥2 moderate or ≥1 severe AECOPD in the 12 months prior to the index date, who were receiving multiple inhaler triple therapy at the index date, and who had a peripheral blood eosinophil count ≥150 cells/µL recorded on the index date. Patients who did not meet all three of the criteria were classified as being in the non-study phenotype.**Abbreviations:** AECOPD, acute exacerbation of COPD; CPRD, clinical practice research datalink; FEV~1~, forced expiratory volume in 1 s; FVC, forced vital capacity; HES, hospital episode statistics; IMD, Index of Multiple Deprivation. Figure S3Unadjusted rates of healthcare resource utilization outcomes during follow-up for patients with and without the study phenotype. Study phenotype is defined as patients with ≥2 moderate or ≥1 severe AECOPD in the 12 months prior to the index date, who were receiving multiple inhaler triple therapy at the index date, and who had a peripheral blood eosinophil count ≥150 cells/µL recorded on the index date. Patients who did not meet all three of the criteria were classified as being in the non-study phenotype.**Abbreviations:** AECOPD, acute exacerbation of COPD; GP, general practitioner. Figure S4Adjusted rate ratios of healthcare resource utilization outcomes during follow-up for (**A**) patients with versus without the primary study phenotype, (**B**) patients with versus without study phenotype~S1~, and (**C**) patients with versus without study phenotype~S2~. Primary study phenotype is defined as patients with ≥2 moderate or ≥1 severe AECOPD in the 12 months prior to the index date, who were receiving multiple inhaler triple therapy at the index date, and who had a peripheral blood eosinophil count ≥150 cells/µL recorded on the index date. For study phenotype~S1~, the peripheral blood eosinophil count required on the index date was increased to ≥300 cells/µL. For study phenotype~S2~, patients were required to have been receiving continuous multiple inhaler triple therapy for ≥12 months prior to the index date. For each analysis, patients who did not meet all three of the criteria were classified as being in the non-study phenotype. Rate ratios adjusted for age, sex, geographical region in England, body mass index, smoking status, comorbidities, Index of Multiple Deprivation (twentiles modeled as a continuous variable), primary care consultations in prior year, and season of index date. Rate ratios were calculated for all outcomes.**Abbreviations:** AECOPD, acute exacerbation of COPD; GP, general practitioner.

[^1]: **Notes:** For each variable, percentages were calculated based on the overall number of patients with data available. ^a^Current asthma: any record for asthma medical diagnosis over the past 12 months prior to index date. ^b^Ascertained during the 12 months prior to the index date.

[^2]: **Abbreviations:** AECOPD, acute exacerbation of COPD; BMI, body mass index; FEV~1~, forced expiratory volume in 1 s; GOLD, Global Initiative for Chronic Obstructive Lung Disease; GERD, gastroesophageal reflux disease; MITT, multiple-inhaler triple therapy; MRC, medical research council; OCS, oral corticosteroid; SD, standard deviation.
